alpha-hydroxyglutarate has been researched along with Leukemia, Myeloid, Acute in 35 studies
2-hydroxyglutarate : A dicarboxylic acid anion obtained by deprotonation of at least one of the carboxy groups of 2-hydroxyglutaric acid.
2-hydroxyglutaric acid : A 2-hydroxydicarboxylic acid that is glutaric acid in which one hydrogen alpha- to a carboxylic acid group is substituted by a hydroxy group.
Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We studied whether 2HG measurements in acute myeloid leukemia (AML) patients correlate with IDH mutations, and whether diagnostic or remission 2HG measurements predict survival." | 2.78 | Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia. ( Abdel-Wahab, O; Agresta, S; Carroll, M; DiNardo, CD; Fernandez, HF; Lazarus, HM; Levine, RL; Litzow, MR; Loren, AW; Luger, SM; Margolis, DJ; Paietta, E; Patel, JP; Perl, AE; Propert, KJ; Rowe, JM; Straley, KS; Sun, Z; Tallman, MS; Yen, K, 2013) |
| "Glutaminase (GLS) is a mitochondrial enzyme that catalyzes the conversion of Gln to glutamate." | 1.43 | Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. ( Baran, N; Cai, T; Chan, SM; Davis, RE; DiNardo, C; Flores, ER; Gonzalez, D; Haferlach, T; Jacamo, R; Konoplev, S; Konopleva, M; Li, W; Lodi, A; Ma, H; Majeti, R; Matre, P; Qi, Y; Samudio, I; Schimmer, AD; Su, X; Sweeney, SR; Tiziani, S; Velez, J; Wang, T, 2016) |
| " Inhibition of glutaminase by allosteric GLS inhibitor bis-2-(5-phenylacetamido-1, 2, 4-thiadiazol-2-yl) ethyl sulfide or by novel, potent, orally bioavailable GLS inhibitor CB-839 reduced intracellular glutamate levels and inhibited growth of AML cells." | 1.43 | Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes. ( Baran, N; Cai, T; Chan, SM; Davis, RE; DiNardo, C; Flores, ER; Gonzalez, D; Haferlach, T; Jacamo, R; Konoplev, S; Konopleva, M; Li, W; Lodi, A; Ma, H; Majeti, R; Matre, P; Qi, Y; Samudio, I; Schimmer, AD; Su, X; Sweeney, SR; Tiziani, S; Velez, J; Wang, T, 2016) |
| "We investigated whether, in acute myeloid leukemia (AML), serum 2-HG would predict the presence of IDH1/2 mutations at diagnosis and provide a marker of minimal residual disease (MRD)." | 1.40 | Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group. ( Auger, N; Barouki, R; Bennaceur-Griscelli, A; Bernard, OA; Berthon, C; Caillot, D; Chachaty, E; Courtier, MH; de Botton, S; Dombret, H; Forget, S; Griscelli, F; Janin, M; Koscielny, S; Leclercq, E; Micol, JB; Mylonas, E; Ottolenghi, C; Pautas, C; Penard-Lacronique, V; Preudhomme, C; Quivoron, C; Rabier, D; Renneville, A; Saada, V; Scourzic, L; Solary, E, 2014) |
| "Acute leukemias are clonal disorders of hematopoiesis wherein a leukemic stem cell (LSC) acquires mutations that confer the capacity for unlimited self-renewal, impaired hematopoietic differentiation, and enhanced proliferation to the leukemic clone." | 1.36 | Metabolism and the leukemic stem cell. ( Abdel-Wahab, O; Levine, RL, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 32 (91.43) | 24.3611 |
| 2020's | 3 (8.57) | 2.80 |
| Authors | Studies |
|---|---|
| Lyu, J | 1 |
| Liu, Y | 1 |
| Gong, L | 1 |
| Chen, M | 1 |
| Madanat, YF | 1 |
| Zhang, Y | 1 |
| Cai, F | 1 |
| Gu, Z | 1 |
| Cao, H | 1 |
| Kaphle, P | 1 |
| Kim, YJ | 1 |
| Kalkan, FN | 1 |
| Stephens, H | 1 |
| Dickerson, KE | 1 |
| Ni, M | 1 |
| Chen, W | 1 |
| Patel, P | 1 |
| Mims, AS | 1 |
| Borate, U | 1 |
| Burd, A | 1 |
| Cai, SF | 1 |
| Yin, CC | 1 |
| You, MJ | 1 |
| Chung, SS | 1 |
| Collins, RH | 1 |
| DeBerardinis, RJ | 1 |
| Liu, X | 1 |
| Xu, J | 1 |
| Thomas, D | 2 |
| Wu, M | 1 |
| Nakauchi, Y | 1 |
| Zheng, M | 1 |
| Thompson-Peach, CAL | 1 |
| Lim, K | 1 |
| Landberg, N | 1 |
| Köhnke, T | 1 |
| Robinson, N | 1 |
| Kaur, S | 1 |
| Kutyna, M | 1 |
| Stafford, M | 1 |
| Hiwase, D | 1 |
| Reinisch, A | 1 |
| Peltz, G | 1 |
| Majeti, R | 3 |
| Gunn, K | 1 |
| Myllykoski, M | 1 |
| Cao, JZ | 1 |
| Ahmed, M | 1 |
| Huang, B | 1 |
| Rouaisnel, B | 1 |
| Diplas, BH | 1 |
| Levitt, MM | 1 |
| Looper, R | 1 |
| Doench, JG | 1 |
| Ligon, KL | 1 |
| Kornblum, HI | 1 |
| McBrayer, SK | 1 |
| Yan, H | 1 |
| Duy, C | 1 |
| Godley, LA | 2 |
| Koivunen, P | 1 |
| Losman, JA | 1 |
| Dang, L | 4 |
| Su, SM | 4 |
| Showalter, MR | 1 |
| Hatakeyama, J | 1 |
| Cajka, T | 1 |
| VanderVorst, K | 1 |
| Carraway, KL | 1 |
| Fiehn, O | 1 |
| Jones, PM | 1 |
| Boriack, R | 1 |
| Struys, EA | 4 |
| Rakheja, D | 1 |
| Montalban-Bravo, G | 1 |
| DiNardo, CD | 2 |
| Lin, P | 1 |
| Luo, Y | 1 |
| Zhu, S | 1 |
| Maggio, D | 1 |
| Yang, H | 3 |
| Hu, C | 1 |
| Wang, J | 1 |
| Zhang, H | 1 |
| Ren, Y | 1 |
| Zhou, X | 1 |
| Mei, C | 1 |
| Ma, L | 1 |
| Xu, W | 1 |
| Ye, L | 1 |
| Zhuang, Z | 1 |
| Jin, J | 2 |
| Tong, H | 1 |
| Bories, PN | 1 |
| Nakib, S | 1 |
| Cynober, L | 1 |
| Alary, AS | 1 |
| Coude, MM | 1 |
| Chevillon, F | 1 |
| Tamburini, J | 1 |
| Birsen, R | 1 |
| Kosmider, O | 1 |
| Bouscary, D | 1 |
| Brunner, AM | 1 |
| Neuberg, DS | 1 |
| Wander, SA | 1 |
| Sadrzadeh, H | 1 |
| Ballen, KK | 1 |
| Amrein, PC | 1 |
| Attar, E | 1 |
| Hobbs, GS | 1 |
| Chen, YB | 1 |
| Perry, A | 1 |
| Connolly, C | 1 |
| Joseph, C | 1 |
| Burke, M | 1 |
| Ramos, A | 1 |
| Galinsky, I | 1 |
| Yen, K | 4 |
| Straley, K | 3 |
| Agresta, S | 3 |
| Adamia, S | 1 |
| Borger, DR | 1 |
| Iafrate, A | 1 |
| Graubert, TA | 1 |
| Stone, RM | 1 |
| Fathi, AT | 1 |
| Wang, F | 1 |
| Travins, J | 1 |
| DeLaBarre, B | 1 |
| Penard-Lacronique, V | 3 |
| Schalm, S | 1 |
| Hansen, E | 1 |
| Kernytsky, A | 1 |
| Liu, W | 1 |
| Gliser, C | 1 |
| Gross, S | 2 |
| Artin, E | 1 |
| Saada, V | 3 |
| Mylonas, E | 2 |
| Quivoron, C | 3 |
| Popovici-Muller, J | 1 |
| Saunders, JO | 1 |
| Salituro, FG | 1 |
| Yan, S | 1 |
| Murray, S | 1 |
| Wei, W | 1 |
| Gao, Y | 1 |
| Dorsch, M | 1 |
| Schenkein, DP | 2 |
| Biller, SA | 1 |
| de Botton, S | 3 |
| Yen, KE | 1 |
| Propert, KJ | 1 |
| Loren, AW | 1 |
| Paietta, E | 1 |
| Sun, Z | 1 |
| Levine, RL | 4 |
| Straley, KS | 1 |
| Patel, JP | 1 |
| Abdel-Wahab, O | 4 |
| Perl, AE | 2 |
| Litzow, MR | 1 |
| Rowe, JM | 1 |
| Lazarus, HM | 1 |
| Fernandez, HF | 1 |
| Margolis, DJ | 1 |
| Tallman, MS | 1 |
| Luger, SM | 1 |
| Carroll, M | 2 |
| Guilhamon, P | 1 |
| Eskandarpour, M | 1 |
| Halai, D | 1 |
| Wilson, GA | 1 |
| Feber, A | 1 |
| Teschendorff, AE | 1 |
| Gomez, V | 1 |
| Hergovich, A | 1 |
| Tirabosco, R | 1 |
| Fernanda Amary, M | 1 |
| Baumhoer, D | 1 |
| Jundt, G | 1 |
| Ross, MT | 1 |
| Flanagan, AM | 1 |
| Beck, S | 1 |
| Wang, JH | 1 |
| Chen, WL | 1 |
| Li, JM | 1 |
| Wu, SF | 1 |
| Chen, TL | 1 |
| Zhu, YM | 1 |
| Zhang, WN | 1 |
| Li, Y | 2 |
| Qiu, YP | 1 |
| Zhao, AH | 1 |
| Mi, JQ | 1 |
| Wang, YG | 1 |
| Ma, QL | 1 |
| Huang, H | 1 |
| Wu, DP | 1 |
| Wang, QR | 1 |
| Yan, XJ | 1 |
| Yan, JS | 1 |
| Li, JY | 1 |
| Wang, S | 1 |
| Huang, XJ | 1 |
| Wang, BS | 1 |
| Jia, W | 1 |
| Shen, Y | 1 |
| Chen, Z | 1 |
| Chen, SJ | 1 |
| Janin, M | 1 |
| Micol, JB | 1 |
| Renneville, A | 1 |
| Koscielny, S | 1 |
| Scourzic, L | 1 |
| Forget, S | 1 |
| Pautas, C | 1 |
| Caillot, D | 1 |
| Preudhomme, C | 1 |
| Dombret, H | 1 |
| Berthon, C | 1 |
| Barouki, R | 1 |
| Rabier, D | 1 |
| Auger, N | 1 |
| Griscelli, F | 1 |
| Chachaty, E | 1 |
| Leclercq, E | 1 |
| Courtier, MH | 1 |
| Bennaceur-Griscelli, A | 1 |
| Solary, E | 1 |
| Bernard, OA | 1 |
| Ottolenghi, C | 1 |
| Wiseman, DH | 2 |
| Small, HF | 1 |
| Wilks, DP | 2 |
| Waddell, ID | 1 |
| Dennis, MW | 2 |
| Ogilvie, DJ | 1 |
| Somervaille, TC | 2 |
| Chan, SM | 2 |
| Corces-Zimmerman, MR | 1 |
| Xavy, S | 1 |
| Rastogi, S | 1 |
| Hong, WJ | 1 |
| Zhao, F | 1 |
| Medeiros, BC | 2 |
| Tyvoll, DA | 1 |
| Clark, CI | 1 |
| Jansen, EE | 2 |
| Salomons, GS | 1 |
| Balss, J | 2 |
| Thiede, C | 2 |
| Bochtler, T | 2 |
| Okun, JG | 3 |
| Saadati, M | 1 |
| Benner, A | 1 |
| Pusch, S | 3 |
| Ehninger, G | 1 |
| Schaich, M | 1 |
| Ho, AD | 3 |
| von Deimling, A | 4 |
| Krämer, A | 4 |
| Heilig, CE | 1 |
| Attar, EC | 1 |
| Chaturvedi, A | 2 |
| Araujo Cruz, MM | 1 |
| Jyotsana, N | 1 |
| Sharma, A | 2 |
| Goparaju, R | 2 |
| Schwarzer, A | 1 |
| Görlich, K | 1 |
| Schottmann, R | 1 |
| Rohde, C | 1 |
| Müller-Tidow, C | 1 |
| Geffers, R | 2 |
| Göhring, G | 1 |
| Ganser, A | 2 |
| Thol, F | 2 |
| Heuser, M | 2 |
| Poinsignon, V | 1 |
| Mercier, L | 1 |
| Nakabayashi, K | 1 |
| David, MD | 1 |
| Lalli, A | 1 |
| Broutin, S | 2 |
| Paci, A | 2 |
| Kingsbury, JM | 1 |
| Shamaprasad, N | 1 |
| Billmyre, RB | 1 |
| Heitman, J | 1 |
| Cardenas, ME | 1 |
| Chen, JY | 1 |
| Lai, YS | 1 |
| Tsai, HJ | 1 |
| Kuo, CC | 1 |
| Yen, BL | 1 |
| Yeh, SP | 1 |
| Sun, HS | 1 |
| Hung, WC | 1 |
| Matre, P | 1 |
| Velez, J | 1 |
| Jacamo, R | 1 |
| Qi, Y | 1 |
| Su, X | 2 |
| Cai, T | 1 |
| Lodi, A | 1 |
| Sweeney, SR | 1 |
| Ma, H | 1 |
| Davis, RE | 1 |
| Baran, N | 1 |
| Haferlach, T | 1 |
| Flores, ER | 1 |
| Gonzalez, D | 1 |
| Konoplev, S | 1 |
| Samudio, I | 1 |
| DiNardo, C | 1 |
| Schimmer, AD | 1 |
| Li, W | 1 |
| Wang, T | 1 |
| Tiziani, S | 1 |
| Konopleva, M | 1 |
| Lemonnier, F | 1 |
| Cairns, RA | 2 |
| Inoue, S | 1 |
| Li, WY | 1 |
| Dupuy, A | 1 |
| Martin, N | 1 |
| Fataccioli, V | 1 |
| Pelletier, R | 1 |
| Wakeham, A | 1 |
| Snow, BE | 1 |
| de Leval, L | 1 |
| Pujals, A | 1 |
| Haioun, C | 1 |
| Tobin, ER | 1 |
| Narayanaswamy, R | 1 |
| Jin, S | 2 |
| Gaulard, P | 1 |
| Mak, TW | 2 |
| Herbst, L | 1 |
| Klett, L | 1 |
| Stichel, D | 1 |
| Kaulfuss, S | 1 |
| Panknin, O | 1 |
| Zimmermann, K | 1 |
| Toschi, L | 1 |
| Neuhaus, R | 1 |
| Haegebarth, A | 1 |
| Rehwinkel, H | 1 |
| Hess-Stumpp, H | 1 |
| Bauser, M | 1 |
| Bakkali, A | 1 |
| Araujo-Cruz, MM | 1 |
| Gabdoulline, R | 1 |
| Rippe, K | 1 |
| Maxmen, A | 1 |
| Minden, MD | 1 |
| Driggers, EM | 1 |
| Bittinger, MA | 1 |
| Jang, HG | 1 |
| Sasaki, M | 1 |
| Fantin, VR | 2 |
| Ward, PS | 1 |
| Patel, J | 1 |
| Wise, DR | 1 |
| Bennett, BD | 1 |
| Coller, HA | 1 |
| Cross, JR | 1 |
| Hedvat, CV | 1 |
| Rabinowitz, JD | 1 |
| Sharp, KA | 1 |
| Thompson, CB | 1 |
| Sellner, L | 1 |
| Capper, D | 1 |
| Meyer, J | 1 |
| Langhans, CD | 2 |
| Hartog, CM | 1 |
| Pfeifer, H | 1 |
| Serve, H | 1 |
| Bhagwat, N | 1 |
| Pollyea, DA | 1 |
| Kohrt, HE | 1 |
| Zhang, B | 1 |
| Zehnder, J | 1 |
| Schenkein, D | 1 |
| Fantin, V | 1 |
| Vasanthakumar, A | 1 |
| Levine, R | 1 |
| Beck, AC | 1 |
| Herold-Mende, C | 1 |
| Buckel, W | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevalence, Correlation With Other Mutant Genes and Clinical Effect of IDH1/2 Mutations in Patients With Acute Myeloid Leukemia. The European IDH Research Alliance[NCT04369287] | 654 participants (Anticipated) | Observational | 2016-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for alpha-hydroxyglutarate and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Isocitrate Dehydrogenase Mutation and (R)-2-Hydroxyglutarate: From Basic Discovery to Therapeutics Development.
Topics: Acetamides; Antineoplastic Agents; Benzeneacetamides; Benzimidazoles; Biomarkers, Tumor; Drug Discov | 2017 |
The role of IDH mutations in acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Enzyme Inhibitors; Epigenesis, Genetic; Glutarates; Humans; Isocitr | 2018 |
Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Topics: Bile Duct Neoplasms; Bone Neoplasms; Central Nervous System Neoplasms; Cholangiocarcinoma; Chondrosa | 2013 |
IDH mutations in cancer and progress toward development of targeted therapeutics.
Topics: Carcinogenesis; Clinical Trials as Topic; Enzyme Inhibitors; Glutarates; Humans; Isocitrate Dehydrog | 2016 |
3 trials available for alpha-hydroxyglutarate and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Serum 2-hydroxyglutarate levels predict isocitrate dehydrogenase mutations and clinical outcome in acute myeloid leukemia.
Topics: Adolescent; Adult; DNA Mutational Analysis; Female; Follow-Up Studies; Glutarates; Humans; Isocitrat | 2013 |
Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.
Topics: China; Disease-Free Survival; DNA Methylation; Female; Gene Expression Regulation, Leukemic; Glutara | 2013 |
Pretreatment d-2-hydroxyglutarate serum levels negatively impact on outcome in IDH1-mutated acute myeloid leukemia.
Topics: Adolescent; Adult; Biomarkers, Tumor; Cytogenetic Analysis; Female; Follow-Up Studies; Glutarates; H | 2016 |
28 other studies available for alpha-hydroxyglutarate and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Disabling Uncompetitive Inhibition of Oncogenic IDH Mutations Drives Acquired Resistance.
Topics: Amino Acids; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; NADP | 2023 |
Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability.
Topics: Enzyme Inhibitors; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation | 2023 |
(R)-2-Hydroxyglutarate Inhibits KDM5 Histone Lysine Demethylases to Drive Transformation in IDH-Mutant Cancers.
Topics: Cell Transformation, Neoplastic; DNA Methylation; Glioma; Glutarates; Histone Demethylases; Histones | 2023 |
Replication Study: The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Topics: Biotransformation; Glutarates; Humans; Isocitrate Dehydrogenase; Ketoglutaric Acids; Leukemia, Myelo | 2017 |
Measurement of Oncometabolites D-2-Hydroxyglutaric Acid and L-2-Hydroxyglutaric Acid.
Topics: Biomarkers, Tumor; Chromatography, Liquid; Glutarates; Humans; Leukemia, Myeloid, Acute; Stereoisome | 2017 |
Isocitrate dehydrogenase 2 mutations correlate with leukemic transformation and are predicted by 2-hydroxyglutarate in myelodysplastic syndromes.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Cohort Studies; Female; | 2018 |
Establishing assay-specific 97.5th percentile upper reference limit for serum D-2-hydroxyglutarate for the management of patients with acute myeloid leukemia.
Topics: Blood Chemical Analysis; Glutarates; Humans; Leukemia, Myeloid, Acute | 2019 |
Isocitrate dehydrogenase 1 and 2 mutations, 2-hydroxyglutarate levels, and response to standard chemotherapy for patients with newly diagnosed acute myeloid leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; F | 2019 |
Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation.
Topics: Allosteric Site; Antineoplastic Agents; Catalytic Domain; Cell Line, Tumor; Cell Proliferation; Cell | 2013 |
Serum 2-hydroxyglutarate production in IDH1- and IDH2-mutated de novo acute myeloid leukemia: a study by the Acute Leukemia French Association group.
Topics: Adult; Aged; Area Under Curve; Biomarkers, Tumor; Female; France; Glutarates; Humans; Isocitrate Deh | 2014 |
Elevated plasma 2-hydroxyglutarate in acute myeloid leukaemia: association with the IDH1 SNP rs11554137 and severe renal impairment.
Topics: Acute Kidney Injury; Biomarkers, Tumor; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myel | 2014 |
Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia.
Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm | 2015 |
Direct comparison of quantitative digital PCR and 2-hydroxyglutarate enantiomeric ratio for IDH mutant allele frequency assessment in myeloid malignancy.
Topics: Gene Frequency; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; Po | 2015 |
Enantiomer-specific and paracrine leukemogenicity of mutant IDH metabolite 2-hydroxyglutarate.
Topics: Animals; Clone Cells; Glutarates; Heterografts; Homeodomain Proteins; Humans; Isocitrate Dehydrogena | 2016 |
Quantitation of isocitrate dehydrogenase (IDH)-induced D and L enantiomers of 2-hydroxyglutaric acid in biological fluids by a fully validated liquid tandem mass spectrometry method, suitable for clinical applications.
Topics: Biomarkers, Tumor; Cell Line, Tumor; Chromatography, Liquid; Glutarates; Humans; Isocitrate Dehydrog | 2016 |
Cancer-associated isocitrate dehydrogenase mutations induce mitochondrial DNA instability.
Topics: Aldehyde Dehydrogenase; Alleles; Cell Line, Tumor; DNA, Mitochondrial; Glioma; Glutarates; Humans; I | 2016 |
The oncometabolite R-2-hydroxyglutarate activates NF-κB-dependent tumor-promoting stromal niche for acute myeloid leukemia cells.
Topics: Complement C5a; Gene Expression Regulation, Leukemic; Glutarates; Humans; Interleukin-6; Interleukin | 2016 |
Inhibiting glutaminase in acute myeloid leukemia: metabolic dependency of selected AML subtypes.
Topics: Antineoplastic Agents; Apoptosis; Benzeneacetamides; Cell Differentiation; Cell Proliferation; Energ | 2016 |
The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development.
Topics: Animals; Biomarkers, Tumor; Flow Cytometry; Gene Expression Regulation, Neoplastic; Genotype; Glutar | 2016 |
Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo.
Topics: Aniline Compounds; Animals; Antineoplastic Agents; Benzimidazoles; Cell Line, Tumor; DNA Methylation | 2017 |
Cancers converge at 2-HG.
Topics: Brain Neoplasms; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myeloid, Acute; Mutation; R | 2010 |
Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations.
Topics: Catalysis; Glutarates; Humans; Isocitrate Dehydrogenase; Ketoglutaric Acids; Leukemia, Myeloid, Acut | 2010 |
The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate.
Topics: Cell Proliferation; Glutarates; Humans; Isocitrate Dehydrogenase; Isocitrates; Ketoglutaric Acids; L | 2010 |
Metabolism and the leukemic stem cell.
Topics: Animals; Cholecalciferol; Glutarates; Hematopoiesis; Hematopoietic Stem Cells; Humans; Hypoxia-Induc | 2010 |
Increased levels of 2-hydroxyglutarate in AML patients with IDH1-R132H and IDH2-R140Q mutations.
Topics: Adult; Aged; Aged, 80 and over; Female; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Myel | 2010 |
Metabolic syndromes and malignant transformation: where the twain shall meet.
Topics: Cell Transformation, Neoplastic; Glioma; Glutarates; Humans; Isocitrate Dehydrogenase; Leukemia, Mye | 2010 |
2-Hydroxyglutarate in IDH mutant acute myeloid leukemia: predicting patient responses, minimal residual disease and correlations with methylcytosine and hydroxymethylcytosine levels.
Topics: 5-Methylcytosine; Aged; Aged, 80 and over; Female; Glutarates; Humans; Isocitrate Dehydrogenase; Leu | 2013 |
Enzymatic assay for quantitative analysis of (D)-2-hydroxyglutarate.
Topics: Alcohol Oxidoreductases; Biomarkers, Tumor; Enzyme Assays; Glutarates; Humans; Isocitrate Dehydrogen | 2012 |